Short-term 12-month consensus price targets issued by analysts covering Abeona Therapeutics average approximately $18.86 per share, with individual forecasts stretching from a conservative low of $14.00 up to an upper target of $28.00, reflecting significant projected upside tied directly to clinical and regulatory milestones.